Global Tuberculosis Therapeutics Industry

NEW YORK, June 28 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Tuberculosis Therapeutics industry

http://www.reportlinker.com/p0197222/Global-Tuberculosis-Therapeutics-industry.html

This report analyzes the Global market for Tuberculosis Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 37 companies including AstraZeneca, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Company, GlaxoSmithKline Plc, Lupin Limited, Novartis AG, Ranbaxy Laboratories Limited, Rusan Pharma Ltd., Rx for Africa, Inc., Sanofi-Aventis SA, Summit Plc, Tibotec BVBA, Otsuka Pharmaceutical Co., Ltd., and Sequella, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

TUBERCULOSIS THERAPEUTICS MCP-6337

A GLOBAL MARKET REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

Tuberculosis: A Reality Check II-1

Evolutionary Battle Against the TB Bug Drives the Future of

the Market II-1

TB Prevalence Statistics: A Current Review II-1

Table 1: Worldwide Prevalence of TB Cases (in 000s) by

Region for the Year (2007) (includes corresponding

Graph/Chart) II-2

Table 2: Worldwide Incidence of TB Cases (in 000s) by Region

for the Year (2007) (includes corresponding Graph/Chart) II-2

Table 3: Worldwide TB Mortality (2009): Breakdown of Number

of TB Deaths (in '000s) by Region (includes corresponding

Graph/Chart) II-2

Effectiveness of Current TB Management Strategies II-2

Table 4: Currently Established TB First-Line Drugs, &

Fixed-Dose Combination Drugs II-3

Table 5: Currently Established TB Second-Line Drugs II-4

Renewed Interest in TB Drugs Development II-4

A Peek into the Current Drug Development Pipeline II-4

TB Drugs in Pipeline as of the Year 2008 II-5

The Importance of Public-Private Partnerships (PPP) II-6

The Promise of New Therapeutic Advancements II-7

Nano Drug Delivery Offers a Ray of Hope II-7

What's The Need of the Hour? II-8

Moving Research to Market II-8

Challenges in Drug Development II-9

Antidotes II-9

Recalibration of Drug Arsenal Against Resistant & HIV Co-

Infected TB Cases II-9

TB Research in Dire Need of Funding II-10

Table 6: Global Tuberculosis R&D Investment for the years

2005 through 2008 (In US$ Million) (includes corresponding

Graph/Chart) II-10

Table 7: Worldwide TB Drugs Market (2007): Percentage Share

Breakdown of Funding by Donor (includes corresponding

Graph/Chart) II-11

Table 8: Worldwide TB R&D Funding (2008): Percentage Share

Breakdown of Allocated Funds by Area of Research (includes

corresponding Graph/Chart) II-11

Table 9: Global Tuberculosis R&D Investment: Breakdown of

R&D Sponsors for the year 2008 (In US$ Million) II-12

Table 10: Global Tuberculosis R&D Investment (2008):

Percentage Share Breakdown of Funds by Donor Type (includes

corresponding Graph/Chart) II-12

Bottleneck in Logistics Need to be Ironed Out II-13

Other Trends & Issues II-13

The State of Research Funding Amidst the Recession II-13

Growth in Drug Resistant TB Cases Drive Second-Line

Therapeutic Drugs Market II-13

HIV Infections: A Major Catalyst in Global Increase of TB II-14

Pharma Companies Called Upon to Focus on TB Drug Development II-14

High Prevalence in Developing Countries offer a Strong

Commercial Opportunity II-14

Table 11: Prevalence of TB in High Burden Countries (2007):

Percentage Share Breakdown of Prevalent Cases by Country

(includes corresponding Graph/Chart) II-15

Table 12: Burden of TB Worldwide (2007): Breakdown of Number

of cases of TB Prevalence ('000s) by Country (includes

corresponding Graph/Chart) II-16

Table 13: Burden of TB in High Burden Countries (2007):

Breakdown of Number of Deaths ('000s) by Country (includes

corresponding Graph/Chart) II-17

A Peek Into the Commitments Voiced by High Burden Countries II-18

MDR-TB on the Rise in Dragon Land II-18

What's the Chinese Government Doing About It? II-18

Indonesia: Pledges Support to TB Drug Research II-19

South Africa Publicizes Its Commitment II-19

Other Statistical Findings II-20

Table 14: Tuberculosis Prevalence in Japan: Breakdown of

Notified Patients by Age Group for the year 2006 through

2008 (includes corresponding Graph/Chart) II-20

Table 15: Tuberculosis Prevalence in Japan: Breakdown of

Notified Patients by Gender for the year 2006 through 2008

(includes corresponding Graph/Chart) II-20

Table 16: Tuberculosis Prevalence in Japan: Breakdown of

Notified Patients by Prefecture/Designated City for the year

2008 (includes corresponding Graph/Chart) II-21

2. DISEASE & TREATMENT OVERVIEW II-22

Tuberculosis (TB): A Prevalent, Yet Neglected Disease II-22

Latent TB Infection II-22

Active TB Infection II-22

A Peek Into the Bacteria Causing the Disease II-22

Types of Tuberculosis II-23

Pulmonary Tuberculosis II-23

Extra Pulmonary Tuberculosis II-23

Diagnosis of TB II-24

Prevention of TB II-24

The Cure II-24

The DOTS Program: A Review II-26

TB Drugs II-26

First line Drugs II-26

Isoniazid II-26

Mode of Action & Dosage II-27

Side Effects II-27

Rifampin II-27

Mode of Action II-28

Side Effects II-28

Pyrazinamide II-28

Dosage II-29

Mode of Action II-29

Side Effects II-29

Ethambutol II-29

Mode of Action II-29

Side Effects II-29

Streptomycin II-29

Second Line Drugs II-30

Aminoglycosides II-30

Mode of Action II-30

Fluoroquinolones II-31

Moxifloxacin (MXF) II-32

Cycloserine II-33

p-aminosalicylic acid (PAS or P) II-33

3. RECENT INDUSTRY ACTIVITY II-34

Across America Financial Services Acquires Apro Bio

Pharmaceutical II-34

Academia Sinica Inks MoU with Infectious Disease Research

Institute II-34

TB Alliance Enters into Collaboration with Tibotec II-34

Rx for Africa Inks Letter of Intent with Rusan Pharma II-35

Johnson & Johnson to Establish Drug Research Centre II-35

Anacor Inks Agreements with Two Non-profit Organizations II-35

Lupin Obtains USFDA Approval II-36

Sequella Commence Phase IB Study for SQ109 II-36

Regional Model TB Center Establishes New Center II-36

AstraZeneca to Commence Safety Studies for TB Drug Candidate II-36

GADD and TIM Enters into Partnership II-37

NWHD to Establish New Tuberculosis Facility II-37

Cadila Pharmaceuticals Launches Risorine II-37

Merck and Eli Lilly Collaborate for TB Treatment II-37

Sanofi-aventis Enters into Collaboration with TB Alliance II-38

Summit Corp Enters into Co development Agreement with Lilly PPP II-38

NITD Collaborates with TB Alliance to Discover New Anti-TB Drugs II-38

Ranbaxy Enters into Alliance with DBT for TB Drug Discovery

and Research II-38

Sanofi pasteur Inks License and Research Agreement with SSI II-39

4. FOCUS ON SELECT GLOBAL PLAYERS II-40

Profiles of generic drug companies & pharma majors, developing

TB drugs in collaboration with not-for profit organizations &

academic institutes II-40

AstraZeneca (UK) II-40

Bayer AG (Germany) II-40

Bristol-Myers Squibb Co. (USA) II-40

Eli Lilly and Company (USA) II-41

GlaxoSmithKline Plc. (UK) II-41

Lupin Limited (India) II-41

Novartis AG (Switzerland) II-42

Ranbaxy Laboratories Limited (India) II-42

Rusan Pharma Ltd., (India) II-43

Rx for Africa, Inc., (USA) II-43

Sanofi-Aventis SA (France) II-44

Summit Plc (UK) II-44

Tibotec BVBA (Belgium) II-45

Otsuka Pharmaceutical Co., Ltd. (Japan) II-45

Sequella, Inc., (USA) II-45

Profiles of key non-profit organizations & academic institutes II-46

Global Alliance for TB Drug Development (USA) II-46

Research Project Pipeline of the Global Alliance for TB Drug

Development As of the Year 2009 II-46

Institute of Microbiology, Chinese Academy of Sciences (China) II-48

5. GLOBAL MARKET PERSPECTIVE II-49

Table 17: World Recent Past, Current & Future Market Analysis

for Tuberculosis (TB) Therapeutics Analyzed with Annual Sales

in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) II-49

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 37 (including Divisions/Subsidiaries - 41)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 13

Canada 1

Japan 2

Europe 16

France 1

Germany 3

The United Kingdom 5

Italy 1

Spain 1

Rest of Europe 5

Asia-Pacific (Excluding Japan) 8

Africa 1

------------------------------------------

To order this report:

Drug and Medication Industry: Global Tuberculosis Therapeutics industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker